Venatorx Pharmaceuticals

What Venatorx Pharmaceuticals does

Venatorx Pharmaceuticals is a clinical-stage biopharmaceutical company developing novel anti-infective therapies for multi-drug-resistant bacterial infections, headquartered in Malvern, Pennsylvania. The company's pipeline is built around proprietary beta-lactam/beta-lactamase inhibitor combinations designed to overcome resistance mechanisms in Gram-negative pathogens. Its two lead assets are cefepime-taniborbactam, a combination antibiotic for which a New Drug Application has been filed for complicated urinary tract infections, and ceftibuten-ledaborbactam, a Phase 3-ready combination that has been out-licensed to Basilea Pharmaceutica for further development and commercialization. These programs target the global antimicrobial resistance crisis, serving an end market of hospitals, infectious-disease specialists, and health systems treating drug-resistant infections.

The company is privately held and venture-backed, founded in 2010 and operating with 51-100 employees. Capital has been raised through a mix of dilutive venture rounds — most recently a Series C Preferred Stock financing in April 2022 led by the AMR Action Fund with participation from Abingworth and other existing investors, and a subsequent ~$24.7 million exempt securities offering — and substantial non-dilutive funding from government and mission-driven sources including the National Institutes of Health, NIAID, the Defense Threat Reduction Agency, the Wellcome Trust, CARB-X, and SBIR. The business model is a hybrid of internal development through regulatory approval (for the lead asset) and partnership-based commercialization via out-licensing (for the second asset), rather than building a commercial sales organization. Scientific leadership rests with founders Luigi Xerri, PhD and Christopher J. Burns, PhD, with operating execution led by COO Ezra Felker and CBO Tony Meehan, PhD, and board oversight by Executive Chairman Manos Perros.

Name

Venatorx Pharmaceuticals

Legal name

Venatorx Pharmaceuticals, Inc.

Website

https://venatorx.com

Company type

Private

Founded year

2010

Operating status

Operating

Headcount range

51–100 employees

Short description

Venatorx Pharmaceuticals is a clinical-stage biopharmaceutical company developing proprietary beta-lactam/beta-lactamase inhibitor antibiotic combinations to treat multi-drug-resistant bacterial infections, with a lead NDA-stage program (cefepime-taniborbactam) for complicated urinary tract infections and a Phase 3-ready asset (ceftibuten-ledaborbactam) out-licensed to Basilea.

Ownership category

akta.pro rank

Product category

Anti-infective Pharmaceuticals

NAICS

Pharmaceutical Preparation Manufacturing (325412), Surgical and Medical Instrument Manufacturing (339112)

SIC

Surgical & Medical Instruments & Apparatus (3841), Wholesale-Drugs, Proprietaries & Druggists' Sundries (5122)

akta.pro primary industry

Primary Care & General Medicine Pharmaceuticals (HLAIAAAA)

Keywords

• Anti-infective therapeutics
• Antibiotic drug development
• Antimicrobial resistance treatments
• Beta-lactamase inhibitor combinations
• Hospital antibiotic pipeline

Headquarters

HQ city

Malvern

HQ country

United States

HQ region

North America

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Technology or R&D, Personnel, Operations, Marketing or Sales

Core offering

Venatorx Pharmaceuticals is a clinical-stage pharmaceutical company that discovers and develops novel anti-infective therapies to treat multi-drug-resistant bacterial and viral infections. Its lead product is cefepime-taniborbactam, a beta-lactam/beta-lactamase inhibitor combination antibiotic for complicated urinary tract infections, with a New Drug Application filed. Its second key asset, ceftibuten-ledaborbactam, is a Phase 3-ready combination antibiotic out-licensed to Basilea Pharmaceutica.

Product overview

Venatorx Pharmaceuticals is a pharmaceutical company focused on developing novel antibiotics targeting drug-resistant bacteria. The company's antibacterial portfolio centers on two key drug candidates: cefepime-taniborbactam (which completed a new drug application submission for urinary tract infections) and ceftibuten-ledaborbactam (a Phase 3-ready asset that was in-licensed to Basilea Pharmaceutica). These products represent a pipeline of treatments addressing the global health crisis caused by antimicrobial resistance.

Differentiator

Problem solved

Functional benefit

Products and services

• Cefepime-taniborbactam A beta-lactam/beta-lactamase inhibitor combination antibiotic being developed for the treatment of complicated urinary tract infections caused by drug-resistant bacteria. Targeted at hospitals, infectious disease specialists, and healthcare systems treating patients with limited therapeutic options.
• Ceftibuten-Ledaborbactam A Phase 3-ready beta-lactam/beta-lactamase inhibitor combination antibiotic for complicated urinary tract infections, out-licensed to Basilea Pharmaceutica for further development and commercialization.

Quantifiable outcome

• New drug application filed for cefepime-taniborbactam for urinary tract infections

Segments1 record

Ideal customer profiles2 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature2 records

Partnerships

One partnership is on record.

• Basilea Pharmaceutica AGcoreTechnology or Integration · 8 January 2026Basilea Pharmaceutica in-licensed the Phase 3-ready antibiotic Ceftibuten-Ledaborbactam from Venatorx Pharmaceuticals. This represents a strategic licensing partnership where Venatorx out-licenses its antibiotic candidate to Basilea for further development and commercialization.

Scale indicators3 records

Recent moves5 records

Expansion highlights4 records

Direct peers

• Basilea Pharmaceutica AG: Swiss-listed specialty anti-infectives company focused on antibiotics and antifungals. Direct comparable to Venatorx — Basilea in-licensed ceftibuten-ledaborbactam from Venatorx, and both companies target drug-resistant bacterial infections with hospital-channel products.
• Iterum Therapeutics: Clinical-stage anti-infectives company developing oral and IV antibiotics for drug-resistant infections, including complicated UTIs. Comparable to Venatorx as a small-cap, antibiotic-focused developer pursuing the same indication space.
• Melinta Therapeutics: Specialty antibiotics company with marketed products for drug-resistant infections (including UTIs). Comparable as a focused anti-infectives commercial/specialty pharma serving hospital channels.
• Entasis Therapeutics: Anti-infectives company (acquired by Innoviva) developing targeted antibiotics for serious drug-resistant infections. Comparable to Venatorx as a small, science-driven developer of novel antibiotic combinations addressing AMR.
• Paratek Pharmaceuticals: Commercial-stage specialty pharma with antibiotic products targeting serious community- and hospital-acquired infections. Comparable to Venatorx as a focused anti-infectives developer/commercializer serving similar hospital channels.
• Nabriva Therapeutics: Biopharmaceutical company developing antibiotics for serious infections including complicated UTIs. Comparable to Venatorx as a small-cap clinical/commercial-stage antibiotic developer in overlapping indications.

Emerging players

• Cidara Therapeutics: Clinical-stage anti-infectives company developing antivirals and antifungal conjugates. Comparable as a small-cap developer addressing drug-resistant infectious diseases, though Cidara's lead assets are antiviral/antifungal rather than antibacterial.

Broad incumbents

• Shionogi & Co., Ltd. Japanese multinational with a strong antibiotics franchise including cefiderocol (an antibacterial for resistant Gram-negative infections). Comparable as an established player with overlapping antibacterial R&D and commercialization capability.
• GSK plc: Global pharma with a meaningful anti-infectives portfolio including gepotidacin (a late-stage antibiotic for UTIs and gonorrhea). Comparable as a broad incumbent competing with Venatorx in the cUTI space with greater commercial reach.
• Pfizer Inc. Global pharmaceutical incumbent with an established antibiotics franchise (e.g., Zavicefta) and broad hospital-channel reach. Comparable as a broad incumbent in the antibacterial space that Venatorx's hospital-targeted products would compete against.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat3 records

Key risks5 records

Key highlights6 records

Customer concentration

• Xx.com/venatorxpharma
• LinkedInlinkedin.com/company/venatorx-pharmaceuticals-inc.

Revenue estimate

Valuation estimate

Number of profiles

Profiles6 records

Funding overview

Funding rounds13 records

Investors11 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Venatorx Pharmaceuticals